GlassScriptPhysician profile
Autumn Marcy
NPI 1043793854
$2,226.59
in general payments reported to CMS, 2019-2025
22 companies · $2,227 in 2025
The $2,227 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,226.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $302.95 | 2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $196.37 | 2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.99 | 2025 | Jardiance |
| Lilly USA, LLC | $171.92 | 2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $169.93 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $161.80 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $148.38 | 2025 | Breztri, Airsupra, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.82 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $120.96 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $115.80 | 2025 | Rexulti |
| Lundbeck LLC | $90.12 | 2025 | Rexulti |
| Pfizer INC. | $76.47 | 2025 | |
| Merck Sharp & Dohme LLC | $74.04 | 2025 | Capvaxive, Gardasil 9, M-M-R II |
| Bayer Healthcare Pharmaceuticals INC. | $62.09 | 2025 | |
| Astellas Pharma US INC | $55.05 | 2025 | Veozah |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $43.17 | 2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $38.69 | 2025 | Auvelity, Symbravo |
| Sumitomo Pharma America, INC. | $33.59 | 2025 | Gemtesa |
| Viatris Specialty LLC | $18.61 | 2025 | Yupelri |
| Esperion Therapeutics, INC. | $17.38 | 2025 | Nexletol |
| Inspire Medical Systems, INC. | $15.39 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $14.07 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Autumn Marcy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.